BiotechTube
Slate Bio

Slate Bio

Cambridge, United States· Est.
slatebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Slate Bio is an early-stage biotech developing a novel class of T regulatory (T reg) cell therapies for autoimmune diseases. The company's platform centers on engineering cytokines to selectively enhance the function and persistence of T reg cells, aiming to provide durable, disease-modifying treatments. Operating from the biotech hub of Cambridge, MA, Slate Bio is positioned in a high-growth therapeutic area with significant unmet medical need. As a private, pre-clinical company, its near-term focus will be on advancing its lead program(s) toward Investigational New Drug (IND) application and securing further venture capital funding.

Autoimmune DiseasesInflammatory Diseases

Technology Platform

Proprietary cytokine engineering platform designed to selectively expand and enhance the function of T regulatory (T reg) cells in vivo for immune tolerance.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The global autoimmune disease market is large and growing, with a significant unmet need for therapies that induce durable remission or tolerance.
Slate Bio's targeted approach to amplifying the body's natural regulatory mechanisms could offer a superior safety and efficacy profile compared to broad immunosuppressants.
Success in even a single major indication could represent a multi-billion dollar opportunity.

Risk Factors

The core scientific risk is the challenge of safely and effectively modulating T reg cells in vivo with engineered cytokines, a novel and unproven therapeutic modality.
The company faces significant development, regulatory, and financial risks as a pre-clinical, pre-revenue startup reliant on venture funding.
Intense competition from other biopharma companies in the immune tolerance space adds further pressure.

Competitive Landscape

Slate Bio competes in the rapidly evolving field of immune tolerance and T reg therapies. Competitors range from large pharma companies with immunology franchises to biotechs developing various approaches, including ex vivo T reg cell therapies (e.g., Sangamo, GentiBio), antibody-based co-stimulation modulators, and other cytokine-targeting agents. Differentiation will depend on the specificity, efficacy, and manufacturability of Slate's engineered cytokine platform.

More companies in United States →